Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIW study in chronic phase CML with inadequate deep molecular response
2024-516328-32-00Phase 2Authorised
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Sep 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pioglitazone and avelumab in chronic myelogenous leukemia (CML) (3 arms), sponsored by Centre Hospitalier de Versailles. Primary endpoint: Deep molecular response by 12 months. Planned start Sep 2024; status: authorised.
02
Drugs
pioglitazoneavelumab
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-516328-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516328-32-00.